Current File : //var/www/html/shaban/duassis/api/public/storage/xwqtu/cache/e8e9f3ef2b2eb3dfd8c65689a7b82727
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:9945:"Cabotegravir oral tablets and a long-acting injectable two-drug regimen consisting of cabotegravir and rilpivirine for HIV treatment has been approved for use in Canada and is currently under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 6,9,10 As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical developmen … Article ViiV closes in on long-acting two drug HIV regimen. Cabenuva reduces the treatment dosing days from 365 days to 12 days per year. A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender … FDA-approved Products for HIV Treatment: Cabenuva, a two-drug regimen consisting of cabotegravir and rilpivirine extended-release injectable suspensions is FDA-approved for HIV treatment. Article Monthly jab of cabotegravir and rilpivirine comparable to daily, three-drug pill for HIV-1. The approval of rilpivirine and cabotegravir by the FDA was based on 2 recent studies, the phase 3 Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study and First Long-Acting Injectable Regimen (FLAIR) study. The recommended oral daily dose is one 30-mg tablet of VOCABRIA (cabotegravir) and one 25-mg tablet of EDURANT (rilpivirine). The first dose of oral therapy should be taken approximately 1 month after the last injection dose of CABENUVA and continued until the day injection dosing is restarted. For … 15-08-2018 (CAB also has been studied, in combination with long-acting rilpivirine, as treatment for people with HIV, see Long-Acting Injectable ART: Cabotegravir + Rilpivirine; this combination has been submitted for FDA approval). Cabotegravir is an antiretroviral drug (ARV) developed by ViiV Healthcare and formulated as an injectable for long-lasting pre-exposure prophylaxis (PrEP). Last week, the FDA approved once-monthly cabotegravir injections plus an injectable version of rilpivirine, sold together under the brand name Cabenuva, as the first complete long-acting HIV treatment regimen. Cabotegravir, as a single drug, has not received any regulatory approval to date either for HIV treatment or HIV prevention. Cabotegravir has not yet been approved for the treatment or prevention of HIV as a single agent by regulatory authorities anywhere in the world. A separate study on cabotegravir’s effectiveness in preventing HIV among men and transgender women also ended early in May for the same reasons. In that companion study HPTN 083, cabotegravir was 66% more effective — the effectiveness range was 38% to 82% — than the oral PrEP. Young women are especially vulnerable to HIV infections. January 21, 2021, 4:44 PM EST SHARE THIS ARTICLE. The FDA also approved Vocabria (cabotegravir, tablet formulation), which should be taken in combination with oral rilpivirine (Edurant) for one month prior to … London, 17 November 2020 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for long-acting, injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP). In recent trials, it … The U.S. FDA has already approved Cabenuva (extended-release cabotegravir and rilpivirine), a once-monthly injection for HIV treatment, and approval for long-acting cabotegravir for PrEP may not be too far in the future. Last December, the FDA declined to approve a new drug application for a long-acting injectable HIV treatment regimen (cabotegravir/ripilvirine) due to technical manufacturing issues, but not for lack of safety or efficacy. ViiV Healthcare is on track to request Food and Drug Administration (FDA) approval of long-acting cabotegravir for PrEP later this year. Cabotegravir PrEP has not yet been approved for use in the U.S. by the Food and Drug Administration. Approval duration is up to 2 months. CAB is Pre-exposure Prophylaxis (PrEP). 18-05-2020. The FDA in the US has approved the first, long-acting, monthly injection treatment for HIV, replacing the need for some to take daily pills. ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen. Both Methods Highly Effective at Preventing HIV Among Men Who Have Sex with Men and Transgender Women. FDA also approved VOCABRIA (cabotegravir) 30 mg tablets which should be taken in combination with oral rilpivirine (EDURANT) for one month prior to … The study randomized participants to one of two arms: 1. CABOTEGRAVIR: GSK126744 Long Acting ( 744 LA) Muller et al, European Journal of Pharmaceutics and Biopharaceutics,2011 Spreen, 7th IAS, 2013; Min, ICAAC, 2009 Taoda, International Congress on Drug Therapy in HIV Infection, 2012 Favorable attributes for PrEP: • High genetic barrier to resistance • PK profile – half life of 21-50 days -- ViiV Healthcare’s long-acting cabotegravir—an injection given every eight weeks—has proved more effective than the daily Truvada form of pre-exposure prophylaxis (PrEP) at reducing the risk of HIV acquisition among cisgender women. PrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. Cabotegravir is in Phase 3 development for HIV prevention. Cabotegravir ®(Vocabria ) is considered experimental, investigational or unproven for ANY other use including the following (this list may not be all inclusive): 1. The announcement comes from ViiV Healthcare, which is majority-owned by GlaxoSmithKline. 66%) in the oral PrEP group. ... GSK-Backed ViiV First To Get FDA Approval For HIV Shots: What You Need To Know. Cross-posted from NIAID Newsroom. Cabotegravir has not yet been approved for the treatment or prevention of HIV as a single agent by regulatory authorities anywhere in the world. The Cabenuva injection contains two active ingredients (cabotegravir and Janssen’s rilpivirine). Premarket Prep + Create your free account. Mechanism of Action: HIV-1 integrase strand transfer inhibitor (INSTI). The approval of Cabenuva is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 patients from 16 countries. Vocabria is not … Cabotegravir (CAB), an analog of dolutegravir, prevents viral DNA integration into the host genome and inhibits HIV replication. 08-03-2019. The long-lasting drug is administered every four weeks. The long-acting cabotegravir injection for PrEP is not yet available for the general public, although the manufacturer, ViiV Healthcare, is seeking regulatory approval for … In a statement provided to a report by the New York Times, Kimberly Smith, MD, MPH, head of research and development at ViiV, said the company now anticipates filing for US Food and Drug Administration (FDA) approval for cabotegravir as an injectable PrEP option in early 2021. Cabotegravir Long-Acting Nanosuspension R H. Müller, et al. GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The long-acting injectable antiretroviral drug cabotegravir, which is being developed by the National Institute of Allergy and Infectious Diseases (NIAID) as a potential for pre-exposure prophylaxis (PrEP) in those at risk of contracting human immunodeficiency virus (HIV), may be preferable to the currently approved PrEP, Gilead’s Truvada (emtricitabine/tenofovir disoproxil … The application for FDA approval of Cabenuva for PrEP will be based on HPTN 083 as well as on HPTN 084, a study in sub-Saharan African women that was stopped in November 2020 on the recommendation of the data safety monitoring board after it was revealed that LA CAB injection was superior to oral FTC/TDF tablets. It’s developed an injectable PrEP treatment called cabotegravir. No updated announcements have been regarding when monthly injectable treatment for HIV will be available. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Adherence to oral PrEP was high, based on random testing finding a high level of the study drug in 87% of all samples tested. It is an integrase inhibitor, the same class of drugs that includes the widely-used treatment drug dolutegravir. only drug product approved for a PrEP indication. The FDA also approved Vocabria (cabotegravir, tablet formulation), which should be taken in combination with oral rilpivirine (Edurant) for one month prior to starting treatment with Cabenuva to ensure the medications are well-tolerated before switching to the extended-release injectable formulation [20]. While waiting for that approval, it is important for … The US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for a long-acting, injectable cabotegravir for HIV pre-exposure-prophylaxis (PrEP), which was recently announced by ViiV Healthcare. Approved by the FDA in PrEP last fall, Descovy uses a different version of tenofovir that carries lower risks of bone and kidney side effects. Conditions Not Covered . Article HIV trial stopped early due to impressive efficacy data. The HPTN 084 enrolled 3,223 women aged 18-45 years old who were at risk for acquiring HIV infection in 20 sites across seven countries in sub-Saharan Africa (Botswana, Kenya, Malawi, South Africa, eSwatini, Uganda and Zimbabwe). Despite demonstrated safety and efficacy, awareness and uptake of Truvada for PrEP in the U.S. were very limited following the approval. ";s:7:"keyword";s:30:"cabotegravir prep fda approval";s:5:"links";s:1039:"<a href="https://api.duassis.com/storage/xwqtu/situational-awareness-navy-seal">Situational Awareness Navy Seal</a>,
<a href="https://api.duassis.com/storage/xwqtu/what-happens-when-you-burn-zinc">What Happens When You Burn Zinc</a>,
<a href="https://api.duassis.com/storage/xwqtu/central-florida-chrysler-jeep-dodge">Central Florida Chrysler Jeep Dodge</a>,
<a href="https://api.duassis.com/storage/xwqtu/burnsville%2C-nc-campgrounds">Burnsville, Nc Campgrounds</a>,
<a href="https://api.duassis.com/storage/xwqtu/list-of-vincentian-missionaries">List Of Vincentian Missionaries</a>,
<a href="https://api.duassis.com/storage/xwqtu/highest-scoring-japanese-ace-of-ww2">Highest Scoring Japanese Ace Of Ww2</a>,
<a href="https://api.duassis.com/storage/xwqtu/tasmania-foodie-road-trip">Tasmania Foodie Road Trip</a>,
<a href="https://api.duassis.com/storage/xwqtu/trainee-a-members-profile">Trainee A Members Profile</a>,
<a href="https://api.duassis.com/storage/xwqtu/eastern-forehand-grip-advantages">Eastern Forehand Grip Advantages</a>,
";s:7:"expired";i:-1;}
Mini Shell